GlobeNewsWire
23 Feb 2026, 14:36 UTC · 34w ago
Impact · against what's priced in
Gilead's acquisition of Arcellx provides an immediate valuation floor for ACLX and expands GILD's oncology pipeline. IBRX and KBLB show strong commercial momentum through hyper-revenue growth and scaled production, respectively, though these are fresh catalysts for the market.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish
Gilead Sciences has agreed to acquire Arcellx for $115 per share in cash plus a contingent value right, totaling an implied equity value of approximately $7.8 billion.
So whatA multi-billion dollar acquisition provides an immediate, high-value exit for ACLX shareholders and signals strong valuation for validated CAR T-cell therapies.
More positive than 99% of claims this week
ImmunityBio reported approximately $113 million in full-year 2025 net product revenue for ANKTIVA, marking a 700% year-over-year increase.
So whatHyper-growth in revenue and expansion into 33 countries validates the commercial viability and scalability of the company's lead immunotherapy asset.
Continue reading
5 related stories
The definitive agreement for Gilead to acquire Arcellx at $115 per share plus a CVR provides a concrete, high-value exit for shareholders.
Read from the article alone
No priced-in read yet
A 700% year-over-year increase in net product revenue to $113 million for ANKTIVA validates the commercial scalability of the immunotherapy asset.
Read from the article alone
No priced-in read yet
The transition to commercial-scale production with the deployment of one million silkworm eggs in Vietnam marks a shift from research to a materials platform.
Read from the article alone
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 94% of claims this week
Kraig Biocraft Laboratories is deploying one million proprietary silkworm eggs across three Vietnam facilities to target monthly production of 10 metric tons of cocoons starting in March.
More positive than 79% of claims this week
The FDA has accepted the Biologics License Application (BLA) for anito-cel, with a PDUFA action date set for December 23, 2026.
So whatEstablishes a concrete regulatory timeline for a potential new foundational treatment for multiple myeloma.
More positive than 67% of claims this week
Which stocks this story touches
More positive than 97% of ticker scores this week
Being acquired by Gilead Sciences at a premium price of $115 per share.
More positive than 97% of ticker scores this week
Reported massive 700% year-over-year revenue growth and expanded regulatory authorizations for ANKTIVA.
More positive than 90% of ticker scores this week
Featured on National Geographic cover and preparing for commercial scale-up of spider silk technology.
More positive than 78% of ticker scores this week
Acquiring Arcellx to strengthen its oncology footprint and gain control of a promising CAR T-cell therapy.
More negative than 69% of ticker scores this week
Mentioned as having been unable to commercialize native-quality synthetic spider silk fibers.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Proactive Investors
1h ago
+79.5%
Price agrees with the score
$115.07 vs $64.11 close before publication (Feb 20) · not market-adjusted
ACLX chart →−5.1%
Price is moving against the score
$8.26 vs $8.70 close before publication (Feb 20) · not market-adjusted
IBRX chart →−23.0%
Price is moving against the score
$0.0828 vs $0.1075 close before publication (Feb 20) · not market-adjusted
KBLB chart →
